Tonix Pharmaceuticals Holding Corp. TNXP R2KPHARMA
Company Overview
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. In addition, the company develops TNX-102 SL, a cyclobenzaprine HCl sublingual tablet for the treatment of major depressive disorder and acute stress reaction/acute stress disorder; TNX-1300, a double-mutant cocaine esterase for the treatment of cocaine intoxication; TNX-1500, an Fc-modified humanized monoclonal antibody to prevent kidney transplant rejection, as well as to treat autoimmune conditions; TNX-4800, a humanized monoclonal antibody for the seasonal prevention of Lyme disease; and TNX-2900, an intranasal oxytocin potentiated with magnesium for the treatment of Prader-Willi syndrome. Further, it is developing TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, and arginine-vasopressin deficiency; TNX-801, a live horsepox vaccine for the prevention of smallpox and mpox; TNX-4200, a small molecule broad-spectrum antiviral agent targeting CD45 for the treatment or prevention of viral disease; TNX-4900, a highly selective small-molecule Sigma-1 receptor antagonist for neuropathic pain; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; and TNX-1800 and TNX-1850, live modified horsepox vaccines for the prevention of COVID. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in Berkeley Heights, New Jersey.
Why Investors Should Care
Revenue has grown at a 29.9% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $13.11M (+29.8% YoY); net profit $-124.02M.
- Trailing 12 Months Year-on-year growth — revenue +577.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 29.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 29.90% |
| 1 Year: | 577.90% |
Stock Price Performance
| 1 Year: | -91.60% |
| 6 Months: | -59.00% |
| 3 Months: | -50.14% |
| 1 Month: | -46.70% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)14.07 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 29.9% over 5 years.
CONS
- Trading 91.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 14 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TNXP Tonix Pharmaceuticals Holding Corp. R2KPHARMA | 5.17 | -0.39 | $88.67M | 0.00% | -51.03% | -81.82% | 29.90% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.99M | 2.48M | 2.21M | 2.82M | 2.43M | 2.00M | 3.29M | 6.88M |
| Operating Income | -3.09M | -5.17M | -6.05M | -7.43M | -9.00M | -9.70M | -11.78M | -13.28M | -13.40M | -14.01M | -9.84M | -7.61M | -5.09M | -4.82M | -5.83M | -6.99M | -6.14M | -5.54M | -6.30M | -5.91M | -7.89M | -7.30M | -14.19M | -12.00M | -20.74M | -23.56M | -18.54M | -26.44M | -23.34M | -29.59M | -33.90M | -29.00M | -28.15M | -21.35M | -77.32M | -15.55M | -16.05M | -28.30M | -33.07M | -41.54M |
| Net Income | -3.09M | -5.16M | -6.04M | -7.42M | -8.99M | -9.68M | -11.76M | -13.25M | -13.36M | -13.98M | -9.81M | -7.58M | -5.06M | -4.78M | -5.79M | -6.93M | -6.09M | -5.48M | -6.23M | -5.84M | -7.84M | -7.27M | -14.18M | -11.99M | -20.65M | -23.55M | -18.53M | -26.42M | -23.14M | -28.98M | -33.01M | -28.36M | -27.98M | -14.94M | -78.78M | -14.21M | -16.83M | -28.27M | -32.01M | -40.19M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.07 | -2.25 | -1.60 | -1.61 | -7.64 | -4.24 | -3.21 | -49.23 | -38.63 | -535.72 | -1,920.85 | -22.68 | -2.84 | -3.86 | -3.59 | -2.93 |
| R&D Expense | 1.64M | 3.55M | 4.08M | 5.22M | - | 6.83M | 8.87M | 10.31M | - | 10.67M | 7.52M | 5.47M | 2.99M | 2.81M | 3.91M | 5.17M | 4.07M | 3.26M | 3.90M | 3.55M | 5.05M | 4.68M | 10.57M | 8.81M | 15.33M | 18.13M | 13.08M | 18.42M | 16.58M | 22.20M | 26.51M | 21.98M | 21.05M | 12.86M | 9.70M | 9.11M | 7.44M | 10.82M | 9.29M | 18.21M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.77M | 10.09M | 13.11M |
| Operating Income | - | - | -1.93M | -3.38M | -6.66M | -10.89M | -27.66M | -48.16M | -38.97M | -21.29M | -26.32M | -28.83M | -50.51M | -92.31M | -112.09M | -118.38M | -136.70M | -125.70M |
| Net Income | -202.00K | -221.00K | -1.96M | -3.47M | -9.45M | -10.88M | -27.62M | -48.05M | -38.84M | -21.12M | -26.09M | -28.62M | -50.46M | -92.29M | -110.22M | -116.66M | -130.04M | -124.02M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | -8.10 | -20.01 | -14,720.25 | -176.60 | -14.57 |
| R&D Expense | - | - | 584.30K | 1.16M | 2.58M | 4.65M | 18.62M | 35.50M | 28.53M | 13.34M | 17.56M | 18.19M | 36.16M | 68.84M | 81.88M | 86.66M | 39.97M | 44.49M |
Balance Sheet (Annual)
Figures in USD.
| Metric | May 2007 | Jun 2007 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | - | - | 184.00K | 425.45K | 2.12M | 8.74M | 39.54M | 47.02M | 27.51M | 26.75M | 26.32M | 14.56M | 98.18M | 240.90M | 225.69M | 154.46M | 162.89M | 277.17M |
| Total Equity | 0 | 0 | -415.00K | -545.00K | -537.00K | -175.00K | -2.45M | 959.00K | 6.51M | 36.09M | 40.26M | 25.36M | 24.62M | 23.66M | 9.42M | 87.65M | 218.72M | 207.18M | 105.53M | 139.56M | 245.15M |
| Cash & Equivalents | - | - | - | - | - | - | - | 1.78M | 8.20M | 38.18M | 19.18M | 18.94M | 25.50M | 25.03M | 11.25M | 77.07M | 178.66M | 120.23M | 24.95M | 98.78M | 207.64M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.56M | 4.67M | - |
| Total Liabilities | - | - | - | - | - | 359.45K | 2.88M | 1.16M | 2.22M | 3.45M | 6.76M | 2.15M | 2.14M | 2.65M | 5.14M | 10.54M | 22.18M | 18.51M | 48.93M | 23.33M | 32.02M |
| Current Liabilities | - | - | - | - | - | 340.28K | 925.28K | 1.14M | 2.21M | 3.38M | 6.65M | 2.12M | 2.13M | 2.65M | 5.13M | 9.82M | 21.72M | 18.18M | 18.88M | 18.31M | 30.84M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.23M | -2.64M | -5.71M | - | - | - | -37.31M | -19.13M | -23.97M | -26.68M | -48.57M | - | -98.05M | -102.00M | -60.92M | -99.84M |
| Investing Cash Flow | -94.37K | 302 | -35.76K | - | - | - | 16.55M | 7.17M | -6.00K | -17.00K | -8.56M | - | -48.15M | -29.07M | -120.00K | -4.53M |
| Financing Cash Flow | 1.39M | 2.61M | 7.49M | - | - | - | 20.50M | 18.52M | 23.54M | 12.92M | 123.11M | - | 87.84M | 36.52M | 134.87M | 214.53M |
| Capital Expenditure | -34.28K | -2.76K | -36.00K | -15.00K | -319.00K | -118.00K | -66.00K | -5.00K | -6.00K | -17.00K | -8.56M | - | -48.15M | -7.89M | -120.00K | -3.37M |
| Free Cash Flow | -1.27M | -2.64M | -5.75M | - | - | - | -37.38M | -19.13M | -23.98M | -26.70M | -57.13M | - | -146.20M | -109.90M | -61.05M | -103.21M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | -58.36M | -94.56M | 73.83M | 110.16M |
| Share Buybacks | - | - | - | - | - | - | - | - | - | - | - | - | - | 13.96M | - | 13.76M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1,523.9% | -1,354.3% | -959.1% |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1,501.8% | -1,288.3% | -946.2% |
| ROE % | 37.1% | 41.2% | 1,122.3% | 141.4% | -985.4% | -167.1% | -76.5% | -119.4% | -153.2% | -85.8% | -110.2% | -303.9% | -57.6% | -42.2% | -53.2% | -110.6% | -93.2% | -50.6% |
| ROCE % | - | - | 1,234.1% | 675.9% | -680.5% | -166.9% | -76.5% | -119.3% | -153.5% | -86.5% | -111.2% | -305.9% | -57.2% | -42.1% | -54.0% | -87.3% | -94.5% | -51.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 8.15% | 1.40M | $10.21M |
| 2 | Point72 Asset Management, L.P. | 6.80% | 1.17M | $8.52M |
| 3 | Millennium Management Llc | 5.64% | 966.93K | $7.06M |
| 4 | AQR Capital Management, LLC | 5.15% | 882.60K | $6.44M |
| 5 | Vanguard Capital Management LLC | 4.03% | 691.89K | $5.05M |
| 6 | Jones Hill Capital LP | 3.65% | 625.43K | $4.57M |
| 7 | Geode Capital Management, LLC | 2.30% | 395.26K | $2.89M |
| 8 | Ishara Investments LP | 1.97% | 338.25K | $2.47M |
| 9 | State Street Corporation | 1.58% | 271.37K | $1.98M |
| 10 | UBS Group AG | 1.35% | 231.68K | $1.69M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TNXP
Tonix Pharmaceuticals Holding Corp. (TNXP) Latest Stock News & Headlines - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiVEFVX3lxTFB5VjRxakltdDdPVEEzY0NYTUE3emRVUTdvUk94dHlycTJucFB2Z1hMa1FpN3hRaXU2TnJNdk8zWEVlaXg4R3c1Rk05ZlFGejYzb3pjTg?oc=5" target="_blank">Tonix Pharmaceuticals Holding Corp. (TNXP) Latest Sto…
TNXP Nov 2026 5.000 put (TNXP261120P00005000) interactive stock chart - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE1KbkRrNXk5X0ZYMFpEdGhVMzFhMGtVbzlLZmlfQ0tURExVWUFESFZuY0E4eUU3bkdfWktxdFpDSXBrLUVqWjVaWGM2SEZDY2hQY0JQdV9YX05oZUlWc2ZWMWZCcGg4elF1bVJnaU13?oc=5" target="_blank">TNXP Nov 2026 5.000…
TNXP Nov 2026 15.000 call (TNXP261120C00015000) stock price, news, quote and history - Yahoo Finance Australia
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE11SW1QNGh2VWVjdllJU2NURWlJNnFkcUJ2anI2SndHNG0wVFlQNjBvMUlyT1BPWG1Ed2E1YzJoRnltSklxVEpnOXZ0eWljOUQ3VUxZLW9za1Z4U3dTaWl6UjhWNXZYQQ?oc=5" target="_blank">TNXP Nov 2026 15.000 call (TN…
TNXP Nov 2026 5.000 put (TNXP261120P00005000) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE5OT24xbWFRRTl0OVpYdDE1NVY0ckNrTGRxWURIUTNTTVRmUHZhQzFBbEFoenpfU3lZYVo2Tk9jbUpKRE5yUHI3bXVBck5JNUduZWJSMGVVcFdkXzhud05KbXpUa2tGUQ?oc=5" target="_blank">TNXP Nov 2026 5.000 put (TNXP…
TNXP Nov 2026 7.500 put (TNXP261120P00007500) stock price, news, quote and history - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE5JbHpRYzZZMEF6QmZON1NkVU5Sd3Roc1VGX3I5UUV1b0xMTjdoQ1hNLS15dHV1NTFXb09jQmlQNGRRSXFYVVFPMHlVUHp5UFNCNlA5SHFYQmVvX1VYLWRMWWxjSkxrdw?oc=5" target="_blank">TNXP Nov 2026 7.500 put (TNXP…
TNXP Nov 2026 10.000 put (TNXP261120P00010000) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE4zQ2RIRzZHb09yVlVwZ1VMVEwzaWpsZ3Y2UVl4RktFcWt1NHlvMUtyVVNTNmJ3aVJvZk9MdnQyUWZSNDQ5elpZOVYtYlAxYzlpTkFfVEhTWWFMdjBwVXBZQktjMXZsUQ?oc=5" target="_blank">TNXP Nov 2026 10.000 put (TNX…
TNXP — Frequently Asked Questions
What is the current share price of Tonix Pharmaceuticals Holding Corp. (TNXP)?
As of 2026-10-23 16:27 PDT, Tonix Pharmaceuticals Holding Corp. (TNXP) trades at $5.17 on NasdaqGS. Its 52-week range is $5.13 to $61.57.
What is the market capitalisation of TNXP?
Tonix Pharmaceuticals Holding Corp. (TNXP) has a market capitalisation of $88.67M on NasdaqGS.
What is the P/E ratio of TNXP?
TNXP trades at a trailing price-to-earnings (P/E) ratio of -0.39. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 0.68.
What is the return on equity (ROE) of TNXP?
TNXP has a return on equity (ROE) of -81.82%. Its return on capital employed (ROCE) is -51.03%.
Is TNXP a good stock to buy?
This page provides a data-driven analysis of Tonix Pharmaceuticals Holding Corp. (TNXP), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.